American Journal of Cardiology
Volume 106, Issue 5 , Pages 650-658, 1 September 2010

Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates

  • Farzin Beygui, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Johanne Silvain, MD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Ana Pena, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Anne Bellemain-Appaix, MD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Jean-Philippe Collet, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Helmut Drexler, MD, PhD

      Affiliations

    • Hochschule Hannover, Hannover, Germany
    • ,
  • Deepak Bhatt, MD

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • Eric Vicaut, MD, PhD

      Affiliations

    • Clinical Research Unit, Lariboisière-Fernand Widal University Hospital–APHP, Paris, France
    • ,
  • Gilles Montalescot, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • Corresponding Author InformationCorresponding author: Tel: (33) 1-4216-3006; fax: (33) 1-4216-2931

Received 9 February 2010; received in revised form 15 April 2010; accepted 15 April 2010. published online 23 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation (ARCHIPELAGO) trial was entirely funded by Sanofi-Aventis, Paris, France.

 Dr. Beygui has received lecture fees from Sanofi-Aventis, Paris, France, Pfizer, New York, New York, and Astellas, Tokyo, Japan. Dr. Silvain has received research grants from Daiichi-Sankyo, Tokyo, Japan, Eli Lilly, Indianapolis, Indiana, and Sanofi-Aventis, Paris, France. Dr. Collet has received research grants from Bristol-Myers Squibb, Markham, Canada, Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, Guerbet Medical, Villepinte, France, Medtronic, Minneapolis, Minnesota, Boston Scientific, Natick, Michigan, Cordis, Bridgewater, New Jersey, Stago, Asnières sur seine, France, and Centocor, Ridgeview, Pennsylvania; consulting fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, and Bristol-Myers Squibb, Markham, Canada; and lecture fees from Bristol-Myers Squibb, Markham, Canada, Sanofi-Aventis, Paris, France, and Eli Lilly, Indianapolis, Indiana. Dr. Montalescot has received research grants from BMS, Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, Guerbet Medical, Villepinte, France, Medtronic, Minneapolis, Minnesota, Boston Scientific, Natick, Michigan, Cordis, Bridgewater, New Jersey, Stago, Asnières sur seine, France, Centocor, Ridgeview, Pennsylvania, ITC Edison, Novi, Michigan, and Pfizer, New York, New York, and consulting fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, BMS, The Medicines Company, Parcipanny, New Jersey, Schering-Plough, Kenilworth, New Jersey, Portola, S San Francisco, California, Novartis, Basle, Switzerland, Menarini, Florence, Italy, Eisai, Woodcliff lake, New Jersey, Daiichi, Bayer, Leverkusen, Germany, and Boehringer Ingelheim, Ingelheim am Rhein, Germany; and lecture fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, BMS, Merck Sharpe and Dohme, Whitehouse station, New Jersey, Cordis, Bridgewater, New Jersey, GlaxoSmithKline, London, United Kingdom, Schering-Plough, Kenilworth, New Jersey, Accumetrics, San Diego, California, AstraZeneca, Wilmington, Delaware, Daiichi, and Menarini, Florence, Italy. Dr. Vicaut has received consulting fees from Pfizer, New York, New York.

PII: S0002-9149(10)00955-0

doi:10.1016/j.amjcard.2010.04.019

American Journal of Cardiology
Volume 106, Issue 5 , Pages 650-658, 1 September 2010

Article Tools

* Image Usage & Resolution